U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C25H23ClN2O7
Molecular Weight 498.912
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BINIFIBRATE

SMILES

CC(C)(OC1=CC=C(Cl)C=C1)C(=O)OC(COC(=O)C2=CC=CN=C2)COC(=O)C3=CN=CC=C3

InChI

InChIKey=BFYRHDVAEJIBON-UHFFFAOYSA-N
InChI=1S/C25H23ClN2O7/c1-25(2,35-20-9-7-19(26)8-10-20)24(31)34-21(15-32-22(29)17-5-3-11-27-13-17)16-33-23(30)18-6-4-12-28-14-18/h3-14,21H,15-16H2,1-2H3

HIDE SMILES / InChI

Description

Binifibrate is an anti-arteriosclerotic and hypolipidaemic agent. It was used under the name Biniwas in patients with hyperlipidemia, however, it is currently withdrawn from the market.

Approval Year

Unknown
149,124

Conditions

ConditionModalityTargetsHighest PhaseProduct
Hyperlipidemia
82
 Primary
Approved
8,583
BINIWAS

PubMed

Sample Use Guides

In Vivo Use Guide
The recommended dose is 600 mg three times daily.
Route of Administration: Oral
In Vitro Use Guide
Unknown
ACTIVE MOIETY
Structure of BINIFIBRATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966